fbpx

Year

2018
Lund, Sweden, 18:00 CET 28 December 2018 – During December, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 December 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,795,917. For more information contact: BONESUPPORT AB Emil...
Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants. This indication is commonly referred to as the de novo indication. Envarsus XR was approved for the prophylaxis of organ rejection in...
Andreas Jurgeit is to join Lundbeckfonden Emerge, the early stage investment unit of the Lundbeck Foundation, as a partner on 1 January 2019. Andreas has been active in various operational and financing roles over the last decade. He was first exposed to biotech as a scientist collaborating with 3V Biosciences during his PhD and later...
The Lundbeck Foundation’s Board of Trustees recently decided to fund new Danish brain research to the tune of DKK 228 million. A considerable proportion of this funding goes to projects focusing on personalised medicine in support of the Danish government’s strategy in this area. Brain disorders cost society more than cancer, diabetes and cardiovascular disease...
Cambridge, UK and Indianapolis, US – 12 December 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 2 clinical trial of APD403 (intravenous and oral amisulpride) in chemotherapy induced nausea and vomiting (CINV) have been published (Herrstedt et al1) in the online edition of...
As a result of the Lundbeck Foundation’s new grant strategy, the Foundation will cover all or part of universities’ project-related, indirect costs in the future. The Foundation’s funding for research has been on the increase for some years, and when the volume of research increases so do the universities’ costs – administration expenses, operation of...
Company Release no. 20/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 06 December 2018   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company’s capital has been increased by 4,948,055 new shares with a nominal value of DKK 0.10 each corresponding to nominally DKK 494,805.50 as a...
Capital increase without preferential subscription rights to the benefit of certain categories of investors Saint-Priest, France, December 6, 2018, 8:00 (Paris time) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces the success of its private placement financing of €7.67 million through a capital increase by the issuance of new shares without preferential subscription...
Capital increase without preferential subscription rights to the benefit of certain categories of investors • Delivery of the new 8,700 sqm production facility expected in 2021 • Financial information update Saint-Priest, France, December 5, 2018, 6:00 p.m. (C.E.T.) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces the launch of a capital increase by...
We are offering a new type of research grant. From 2019, researchers can apply for a Lundbeck Foundation Professorship. A Lundbeck Foundation Professor is an internationally recognised researcher and research director who makes a significant contribution to neuroscience research in the broadest sense, while also developing and mentoring junior researchers. The aim of the professorship...
1 2 3 15

News

Open for applications for postdoc scholarships
11. July 2019
Shorter hospital stays after hip and knee surgery
8. July 2019
The Lundbeck Foundation is seeking new fellows
8. July 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge